Retatrutide + Tirzepatide (Blend)

Overview

PeptideXpo's Retatrutide + Tirzepatide blend is a single-vial research co-formulation holding 20 mg of retatrutide alongside 40 mg of tirzepatide. Retatrutide (LY3437943) is a triple incretin agonist that engages the GLP-1, GIP, and glucagon receptors; tirzepatide (LY3298176) is a dual GIP/GLP-1 agonist. Each is an incretin-mimetic peptide backed by its own substantial clinical dataset — but the fixed-ratio pairing is a formulation convenience for research only, has never been evaluated as a combination product in a dedicated clinical trial, and should not be assumed to have any pharmacology beyond the additive behavior of its two well-characterized components. PeptideXpo supplies the blend as a lyophilized powder with per-component analytical documentation: the batch COA reports each peptide's identity and RP-HPLC purity plus the verified fill ratio, rather than a single combined purity figure — the correct way to release a two-active blend. Buyers who need to vary the ratio, or who want the two peptides as separate vials, should order the single-component SKUs instead. Supplied for research use only, not for human or veterinary use.

Who buys this, and why

Custom-blend buyers are almost always OEM clients building a branded product around a specific ratio of two or more peptides. The development workflow is collaborative: ratio target, analytical method to verify it, stability protocol in the chosen carrier, and packaging selection are all defined in the OEM brief before the first commercial run. Sample-stage volumes are usually 5-10 g of finished blend; commercial MOQ depends on the components.

Primary buyer fit: academic and contract research laboratories.

Specifications

CAS

(blend — Retatrutide 2381089-83-2 + Tirzepatide 2023788-19-2)

Appearance

White lyophilized powder

Purity (HPLC)

Per-component (see COA)

Strength

60 mg

Packaging

10 vials/box · base pack (multiples of 10)

MOQ

On request

Lead time

7–14 days

Storage

-20°C lyophilized; 2–8°C reconstituted, protect from light

Documentation available on request

• Certificate of Analysis (COA)
• Ratio-verification HPLC
• Mass-spec identity of each component
• Stability of the blend (matrix-specific)
• Bacterial endotoxin (LAL, USP <85>)
• Sterile-fill documentation (where applicable)
• SDS / MSDS
• Private-label / OEM specification sheet

Regulatory note

Research-use-only reference material; not for human or veterinary use. The fixed combination is not a clinically validated product.

Frequently asked questions